Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Bristol’s Involvement in Sprycel Trial Could Contravene Ethics Code, but Not PAL: Probe
A third-party investigation found that Bristol-Myers K.K. most likely violated the health ministry’s ethical guidelines with its involvement in an investigator-initiated clinical trial on Sprycel (dasatinib), the company’s chronic myeloid leukemia (CML) drug. The multi-center trial was conducted to examine…
To read the full story
Related Article
- Bristol-Myers Reprimanded by JPMA over Misconduct in Sprycel Trial
December 19, 2014
- BMKK Asks Major Law Firm to Conduct Independent Investigation of Clinical Research on Sprycel
July 4, 2014
- BMKK to Begin Third-Party Investigation into Company Involvement in Sprycel Trial
June 26, 2014
- Univ. Says Data Leaks in SIGN Run Afoul of Personal Information Law, Newly Finds Bristol’s Misconduct
June 25, 2014
BUSINESS
- Merck Biopharma Starts Japan PIII Trial of LH/FSH Combo
July 17, 2026
- Eisai’s Dayvigo Accepted for EMA Review
July 17, 2026
- AbbVie Files Maviret for Acute Hepatitis C
July 17, 2026
- FRONTEO, Santen Advance AI Drug Discovery Project to Second Phase
July 17, 2026
- Ferring’s Adstiladrin, Boehringer’s Jascayd Hit Market; Haizexin Due July 28
July 16, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…